{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:24:54Z","timestamp":1782779094006,"version":"3.54.5"},"reference-count":35,"publisher":"Impact Journals, LLC","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,6]]},"DOI":"10.18632\/oncotarget.11135","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T14:05:11Z","timestamp":1470751511000},"page":"58396-58404","source":"Crossref","is-referenced-by-count":24,"title":["The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)\/T-cell lymphoma, nasal type"],"prefix":"10.18632","volume":"7","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Nan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Cancer Hospital, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"1","first-page":"285","volume-title":"WHO classification of tumors of haematopoietic and lymphoid tissue (IARC WHO classification of tumors)","author":"Harris","year":"2008","edition":"4"},{"key":"2","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Liang","year":"2009","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdp418","article-title":"Prognostic factors for mature natural killer (NK) cell neoplasms:aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type","volume":"21","author":"Kurokawa","year":"2010","journal-title":"Annals of Oncology"},{"key":"4","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89:3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdi037","article-title":"Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years","volume":"16","author":"Kwong","year":"2005","journal-title":"Annals of Oncology"},{"key":"6","doi-asserted-by":"crossref","unstructured":"The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathology International. 2000; 50:696\u2013702.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2003-12-4197","article-title":"Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients","volume":"104","author":"Kwong","year":"2004","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/10428190902803669","article-title":"Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer\/T-cell lymphoma","volume":"50","author":"Kim","year":"2009","journal-title":"Leukemia & Lymphoma"},{"key":"9","doi-asserted-by":"publisher","first-page":"30317","DOI":"10.18632\/oncotarget.4505","article-title":"Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK\/T cell lymphoma in the era of asparaginase","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","article-title":"CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma?","volume":"12","author":"Park","year":"2001","journal-title":"Annals of Oncology"},{"key":"11","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6602502","article-title":"Nasal-type NK\/T cell lymphoma: clinical features and treatment outcome","volume":"92","author":"Ko","year":"2005","journal-title":"British Journal of Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.leu.2403262","article-title":"Aggressive natural killer (NK)-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells","volume":"18","author":"Oshimi","year":"2004","journal-title":"Leukemia"},{"key":"13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1756-8722-6-86","article-title":"Extranodal natural killer\/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group","volume":"6","author":"Suh","year":"2013","journal-title":"Journal of Hematology & Oncology"},{"key":"14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.V93.2.599","article-title":"P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of Pglycoproteinfunction by cyclosporin A and its analogue, PSC833","volume":"93","author":"Oshimi","year":"1999","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","article-title":"CD3-CD56 non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance","volume":"89","author":"Fauchet","year":"1997","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK Cell tumor study group study","volume":"29","author":"Kimura","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"17","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of Lasparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/Tcell lymphoma, a phase 2 study","volume":"117","author":"de Leval","year":"2011","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-0609.2009.01395.x","article-title":"Activity and safety of combination chemotherapy with methotrexate, ifosfamide, lasparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study","volume":"84","author":"Sugimoto","year":"2010","journal-title":"European Journal of Haematology"},{"key":"19","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Chim","year":"2012","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2011.40.7098","article-title":"To SMILE or not: supportive care matters","volume":"30","author":"Lim","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"21","first-page":"388","article-title":"Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment","volume":"30","author":"Wilson","year":"1995","journal-title":"Formulary"},{"key":"22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Baccarani","year":"2010","journal-title":"Annals of Oncology"},{"key":"23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12032-012-0350-5","article-title":"Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma","volume":"30","author":"Guo","year":"2013","journal-title":"Medical Oncology"},{"key":"24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Canellos","year":"2007","journal-title":"Annals of Oncology"},{"key":"25","first-page":"13","volume-title":"Chemotherapeutic drug sensitivity experiment of SNK-6 and Hut-78 cell lines in vitro and multidrug resistance gene detection[D].","author":"Zhang","year":"2011"},{"key":"26","first-page":"539","article-title":"TUBB3 and ERCC1 expression levels are correlated with chemosensitivity to platinum and anti-microtubule reagents in human lymphoma cell lines","volume":"33","author":"Sheng","year":"2012","journal-title":"Journal of Xi'an Jiaotong University(Medical sciences)"},{"key":"27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4149\/neo_2014_029","article-title":"Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer\/T-cell lymphoma","volume":"61","author":"Zhang","year":"2014","journal-title":"Neoplasma"},{"key":"28","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-014-2136-7","article-title":"Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed\/refractory extranodal NK\/T cell lymphoma: a retrospective study of 17 patients","volume":"93","author":"Li","year":"2014","journal-title":"Annals of Hematology"},{"key":"29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","article-title":"Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract","volume":"70","author":"Lu","year":"2008","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"30","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12185-010-0720-8","article-title":"Treatment of localized extranodal NK\/T cell lymphoma, nasal type","volume":"92","author":"Kim","year":"2010","journal-title":"International Journal of Hematology"},{"key":"31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2003-05-1401","article-title":"Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index","volume":"103","author":"Kwong","year":"2004","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-5-27","article-title":"Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK\/T cell lymphoma","volume":"5","author":"Salles","year":"2012","journal-title":"Journal of Hematology & Oncology"},{"key":"33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/cncr.21656","article-title":"Extranodal natural killer\/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters","volume":"106","author":"Ito","year":"2006","journal-title":"Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Pyo","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"35","first-page":"5s","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type\u2014A new staging system from CSWOG\u2014A multicenter study","volume":"32","author":"Raj Shrestha","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T11:54:48Z","timestamp":1596714888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":35,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2016,9,6]]}},"alternative-id":["11135","27517317"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11135","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}